Table 1 Baseline characteristics of participants and comparison between groups of patients with and without NSAIDs use

Age, y

82.3 (7.4)

81 (7)

83.1 (7.5)

Sex, male n, (%)

69 (26.4)

21 (22.3)

48 (28.7)

BMI, kg/m²

20.6 [18.2, 23]

21 [19, 24.1]

20.1 [17.7, 22.6]

Comorbid conditions n, (%)

 Cardiac disease

41 (15.7)

9 (9.5)

32 (19.2)

 Hypertension

167 (64)

61 (64.9)

106 (63.5)

 Dementia

28 (10.7)

11 (11.7)

17 (10.2)

 Parkinson’s disease

5 (1.9)

2 (2.1)

3 (1.8)

 Epilepsy

7 (2.7)

2 (2.1)

5 (3)

 Cerebrovascular disease

36 (13.8)

13 (13.8)

23 (13.8)

 Higher brain dysfunction

2 (0.8)

1 (1.1)

1 (0.6)

Paralysis n, (%)

 upper limbs

7 (2.7)

2 (2.1)

5 (3)

Fracture Sites n, (%)

 Femoral

 Lumbar Spine

 Thoracic Spine

 Pelvic

 Patellar

 Others

110 (42.1)

54 (20.7)

41 (15.8)

20 (7.7)

15 (5.7)

21 (8)

30 (31.9)

22 (23.4)

24 (25.5)

8 (8.5)

3 (3.2)

7 (7.5)

80 (47.9)

32 (19.2)

17 (10.2)

12 (7.2)

12 (7.2)

14 (8.4)

0.012

0.417

0.001

0.699

0.183

0.790

FIM, score

-Total

74 [59, 89.5]

73 [59, 87.3]

75 [59, 90]

-Motor

47 [31, 58]

47 [30, 64.2]

48 [32, 58]

-Cognitive

29 [25, 35]

32 [25.5, 35]

28 [24, 35]

Laboratory data

 Alb, g/dL

3.5 (0.2)

3.5 (0.4)

3.5 (0.3)

 CRP, mg/dL

0.3 [0.1, 1.1]

0.4 (0.1, 1.1)

0.3 (0.2, 1.2)

Family Support n, (%)

250 (95.8)

90 (95.7)

160 (95.8)

Medication data

 Number of total drugs

7 [4, 9]

7 [5, 9]

6 [4, 9]

 Number of medication review

4 [2, 7]

4 [3, 7]

4 [2, 6]

 Acetaminophen use n, (%)

94 (36)

22 (23.4)

72 (43.1)

 Weak opioid use n, (%)

6 (2.3)

2 (2.1)

4 (2.4)